Laurus Labs Q2 FY27 Results: Revenue Up 33% to ₹2,206 Cr; Acquires Galenvs Sciences
Laurus Labs reported Q2 FY27 revenue of ₹2,206 crore, up 33% YoY, with net profit at ₹441 crore. For H1 FY27, revenue reached ₹4,233 crore, up 31% YoY. The company announced the acquisition of 60% of Galenvs Sciences to bolster its CDMO capabilities. An interim dividend of ₹1.00 per share was declared.
The significant financial growth and the strategic acquisition of a specialized technology company are material events that are expected to have a substantial impact on the company's future performance and market position.
The company reported strong year-on-year growth in revenue, profit, and EBITDA for both the quarter and half-year. The acquisition of Galenvs Sciences is a strategic positive move to expand its capabilities in a growing market. The declaration of an interim dividend also signals financial health.
Laurus Labs Limited announced its financial results for the quarter and half-year ended September 30, 2026, reporting a strong performance with a 33% year-on-year increase in revenue to ₹2,206 crore for Q2 FY27.
For the second quarter of FY27, the company posted a net profit of ₹441 crore, a significant jump of 126% from the previous year, with Earnings Per Share (EPS) at ₹8.2. EBITDA for the quarter stood at ₹762 crore, marking a 78% increase, and EBITDA margins improved to 34.5%. The company also reported a Gross Margin of 63.0% for the quarter.
During the first half of FY27 (H1 FY27), Laurus Labs recorded revenue of ₹4,233 crore, up 31% year-on-year. The EBITDA for H1 FY27 was ₹1,406 crore, a 72% increase, with EBITDA margins at 33.2%. Net profit for the half-year surged by 126% to ₹809 crore, and EPS was ₹15.0.
In a strategic move, Laurus Labs also announced the acquisition of a 60% stake in Canada-based Galenvs Sciences, a company specializing in oligonucleotide technologies and precision magnetic nanoparticles. This acquisition, valued at a pre-money valuation of USD 3.50 million with an investment of USD 3.75 million, aims to strengthen Laurus Labs' integrated CDMO offering in the rapidly growing oligonucleotide market.
The company declared an interim dividend of ₹1.00 per share. The earnings conference call to discuss these results is scheduled for Thursday, October 29, 2026, at 5:00 PM IST.
What to do with a filing like this
Laurus Labs Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Laurus Labs Limited. Read the original for the full detail.